medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2005, Number 3

<< Back Next >>

Rev Esp Med Quir 2005; 10 (3)

El dilema del antígeno prostático específico para cáncer de próstata de difícil localización

Jiménez MRA

Language: Spanish
References: 18
Page: 19-24
PDF size: 218.52 Kb.


ABSTRACT

The prostate cancer is one of the main causes of mortality in men over 50 years old, thus in the search of a tumor marker, the prostate specific antigen (PSA) was discovered. The PSA, digital rectal examination, transrectal ultrasound and prostate biopsy makes possible the early detection of prostate cancer. 70% of the patients are in clinical stage T1C, being the key for the diagnosis that the PSA doesn’t rise higher than 10 ng/ml. The elevation of the PSA is not synonymous of cancer, but it indicates a prostate disease and the need of further evaluation to find the cause. None malignant conditions of the prostate can be associated with a high PSA, like: Prostatic intraepithelial neoplasia, ischemia and prostate infarction. The PSA doesn’t have specificity to be used as scrutiny studies, especially what is called the gray area of the PSA (4.1-10 ng/ml). To increase its sensibility and specificity there have been design a series of variables: total Value according to age, density, free fraction, relationship between free PSA and total PSA, and density of the PSA in the transition area of the prostate. There is no specific agreement if the age influences in the PSA, however Oesterling described that the PSA correlates with the age and prostate volume.


REFERENCES

  1. Walsh Patrick C. MD. Campbell Urologia. 6ta edición. Buenos Aires: Editorial Médica Panamericana, 1994:1155-1219.

  2. Huggins Charles. Conocimientos actuales sobre el cáncer de próstata. Revista mexicana de urología 1949; XX(5): 220-226.

  3. Leport L, Lawson RK. Enfermedades de la próstata. Buenos aires: Editorial Médica Panamericana, 1994:341-55.

  4. Kurtiyama M, Wnag MC, Papsidero LD, Kilian CS, Shimano T, Valenzuela L et al. Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980, 40: 4658.

  5. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwinw E. Prostatic specific antigen and prostatic a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317:909.

  6. Stamey TA. Second stanford conference on international standardization of prostate specific antigen immunoassays: September 1 and 2, 1994. Urology 1995; 45:173-83.

  7. Agha AH, Schechter E, Roy JB, Culkin DJ. Prostate specific antigen is metabolized in the liver. J Urol 1996; 155: 1332-35.

  8. Kojima M, Babaian RJ. Algorithms for early detection of prostate cancer 1994; 75 (suppl): 1860-67.

  9. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in community-based population of healthy men: stablishment of age-specific reference ranges. JAMA 1993; 270: 860-64.

  10. Cooner, W.H.: Prostate-specific antigen, digital rectal examination, and tranrectal ultrasonic examination of the prostate in prostate cancer detection. Monogr. Urol., 12:3, 1991.

  11. Scardino Pt, Carrol PR, de Kernion JB, Miles BJ. Prostate cancer treatment. Stage by AUA office of education, 1996; seminar 9655: Scardino 1-11.

  12. Zonana Farca Elias, Ricardez Espinosa Abel Antonio. Estudios de laboratorio y gabinete. Cáncer de próstata. Programa de actualización continua para el urólogo. Parte 1, 1998.

  13. Bengman, Chris H.; Reirbergen, John B. W.; Kranse, Ries; The free to total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997; 157 (6): 2191-2196.

  14. Lee F, Littrup PJ, y col. Prostate cancere detection in clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 1431146-54.

  15. Ketch DW, Catalona WJ, Smith DS. Serial prostate biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994, 151:1571

  16. Hodge KK, McNeal JE, Terris MK y col. Random systematic versus directed ultrasound-guided transrectal core biopsies of the prostate. J Urol 1989; 142:71.

  17. Cookson Michael S. Technical refinements of transrectal ultrasound-guided needle biopsy and re-biopsy of the prostate. 1999 AUA metting seminar.

  18. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in community-based population of healthy men: stablishment of age-specific reference ranges. JAMA 1993; 270: 860-64.




2020     |     www.medigraphic.com